"老年期"の骨粗鬆症は再検討される
1Joint Department of Medicine, Beth Israel Hospital, Boston, MA.
JAMA
|February 17, 1989
まとめ
骨粗鬆症は高齢の女性に不釣り合いな影響を与えているが,現在の治療法は若い人に焦点を当てている. 70歳以上の女性のための効果的な骨粗鬆症療法を開発するために,研究が緊急に必要とされています.
科学分野:
- ゲロントロジーはゲロントロジーの学科です.
- 骨代謝についてです.
- ゲリアトリック・メディシン (老年医学)
背景:
- 骨粗鬆症は重大な健康問題であり,特に70歳以上の女性に影響します.
- オステオポロシスの現在の研究と治療は,主に閉経前期の女性を対象としています.
- 70歳以上の閉経前と閉経後の女性の骨の健康には重大な違いがあります.
研究 の 目的:
- 高齢の女性に対する現在の骨粗鬆症治療の不十分さを強調する.
- 70歳以上の女性の特定の骨代謝と骨折リスクに合わせた研究の必要性を強調する.
- 高齢者における骨粗鬆症の予防と治療のための将来の研究方向を提案する.
主な方法:
- 閉経前期の女性の骨粗鬆症に関する既存の文献のレビュー,高齢女性との比較.
- 骨のミネラル代謝,骨の喪失率,骨の構造的整合性の差異の分析.
- 高齢の女性において顕著なリスク要因と骨折のタイプを調査.
主要な成果:
- 現在の骨粗鬆症の治療法は,骨の損失が減速または停止し,骨の質が損なわれるため,高齢女性では効果が低下しています.
- 既存の治療法では,70歳以上の女性の骨の独特の生理学的変化に適切に対処できない可能性があります.
- この集団における骨粗鬆症の影響を緩和する現在の手法の有効性は限られている.
結論:
- 現在の骨粗鬆症管理戦略は,70歳以上の女性の再評価を必要とする.
- 高齢の女性の骨粗鬆症に対する標的と効果的な介入の開発には,さらなる研究が不可欠です.
- 将来の研究は,骨折の予防と治療の成果を改善するために,高齢女性の特定のニーズとリスクプロファイルに焦点を当てるべきです.
関連する概念動画
Bone Remodeling
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
Osteoclasts in Bone Remodeling
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
Bone Disorders
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Role of Vitamins in Maintaining Bone Health
The growth and maintenance of bone are regulated by a combination of nutritional factors, including vitamins, such as vitamin A, B12, C, D, and K.
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...


